Evolution of surveillance of measles, mumps, and rubella in England and Wales: Providing the platform for evidence-based vaccination policy

Epidemiologic Reviews

Volumn 24, Issue 2, 2002, Pages 125-136

  Vyse, A J ^a,b   Gay, N J ^a   White, J M ^a   Ramsay, M E ^a   Brown, D W G ^b   Cohen, B J ^b   Hesketh, L M ^c   Morgan Capner, P ^c   Miller, E ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b CENTRAL PUBLIC HEALTH LABORATORY   (United Kingdom)

^c ROYAL PRESTON HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

AGE DISTRIBUTION; ANTIBODY RESPONSE; ANTIBODY TITER; EPIDEMIOLOGICAL DATA; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HEALTH PROGRAM; HUMAN; MEASLES; MEASLES VACCINATION; MEASLES VIRUS; MUMPS; MUMPS VIRUS; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; REVIEW; RUBELLA; RUBELLA VIRUS; UNITED KINGDOM;

ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; ENGLAND; HEALTH POLICY; HUMANS; IMMUNIZATION SCHEDULE; INFANT; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MUMPS; POPULATION SURVEILLANCE; RUBELLA; VACCINATION; WALES;

EID: 0038740726     PISSN: 0193936X     EISSN: None     Source Type: Journal    
DOI: 10.1093/epirev/mxf002     Document Type: Review

References (62)

1. Lambert PH. Research priorities for the WHO Global Programme for Vaccines and Immunization. Dev Biol Stand 1996;87:45-9.
2. Griffin D, Bellini W. Measles virus. In: Fields B, Knipe D, Chanock R, et al, eds. Virology. Philadelphia, PA: LippincottRaven, 1996:1267-312.
3. Wolinsky J. Mumps virus. In: Fields B, Knipe D, Chanock R, et al, eds. Virology. Philadelphia, PA: Lippincott-Raven, 1996:1243-65.
4. Wolinsky J. Rubella. In: Fields B, Knipe D, Chanock R, et al, eds. Virology. Philadelphia, PA: Lippincott-Raven, 1996:899-921.
5. Gregg N. Congenital cataract following German measles in the mother. Trans Ophthalmol Soc Aust 1941;3:35-46.
6. Ramsay M, Gay N, Miller E, et al. The epidemiology of measles in England and Wales: rationale for the 1994 national vaccination campaign. Commun Dis Rep Rev 1994;4:R141-6.
7. Miller E, Waight P, Vurdien J, et al. Rubella surveillance to December 1990: a joint report from the PHLS and National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev 1991;1:R33-7.
8. Miller C. MMR vaccine: a new initiative. Practitioner 1989;233:63-6.
9. Gay N, Ramsay M, Cohen B, et al. The epidemiology of measles in England and Wales since the 1994 vaccination campaign. Commun Dis Rep Rev 1997;7:R17-21.
10. Salisbury DM, Horsley SD. Measles campaign. (Letter). BMJ 1995;310:1334.
11. Communicable Disease Surveillance Centre. A second dose of MMR vaccine for children in the United Kingdom. Commun Dis Rep CDR Wkly 1996;6:259.
12. World Health Assembly. WHA4232. In: Handbook of resolutions and decisions of the World Health Assembly and the Executive Board. Vol III, 2nd ed. (1985-89). Geneva, Switzerland: World Health Organization, 1990:56-7.
13. Begg N, Gill O, White J. COVER (Cover of Vaccination Evaluated Rapidly): description of the England and Wales scheme. Public Health 1989;103:81-9.
14. McCormick A. The notification of infectious diseases in England and Wales. Commun Dis Rep 1993;3:R19-25.
15. Hogan P. Viral exanthems in childhood. Australas J Dermatol 1996;37(suppl 1):S14-16.
16. Tait D, Ward K, Brown D, et al. Measles and rubella misdiagnosed in infants as exanthem subitum. BMJ 1996;312:101-2.
17. Malamud D. Oral diagnostic testing for detecting human immunodeficiency virus-1 antibodies: a technology whose time has come. Am J Med 1997;102:9-14.
18. Mortimer P, Parry J. The use of saliva for viral diagnosis and screening. Epidemiol Infect 1988;101:197-201.
19. Mortimer P, Parry J. Non-invasive virological diagnosis: are saliva and urine specimens adequate substitutes for blood? Rev Med Virol 1991;1:73-8.
20. Parry J. Simple and reliable salivary tests for HIV and hepatitis A and B virus diagnosis and surveillance. Ann N Y Acad Sci 1993;694:216-33.
21. Brown D, Ramsay M, Richards A, et al. Salivary diagnosis of measles: a study of notified cases in the United Kingdom, 1991-3. BMJ 1994;308:1015-17.
22. Perry K, Brown D, Parry J, et al. Detection of measles, mumps and rubella antibodies in saliva using antibody capture radioimmunoassay. J Med Virol 1993;40:235-40.
23. Gay N, Miller E, Hesketh L, et al. Mumps surveillance in England and Wales supports introduction of two dose vaccination schedule. Commun Dis Rep Rev 1997;7:R21-6.
24. Ramsay M, Brugha R, Brown D, et al. Salivary diagnosis of rubella: a study of notified cases in the United Kingdom, 1991-4. Epidemiol Infect 1998;120:315-19.
25. Ramsay M, Brugha R, Brown D. Surveillance of measles in England and Wales: implications of a national saliva testing programme. Bull World Health Organ 1997;75:515-21.
26. Jin L, Richards A, Brown D. Development of a dual target-PCR for detection and characterization of measles virus in clinical specimens. Mol Cell Probes 1996;10:191-200.
27. Jin L, Beard S, Brown D. Genetic heterogeneity of mumps virus in the United Kingdom: identification of two new genotypes. J Infect Dis 1999;180:829-33.
28. Cohen BJ, Jin L, Brown DW, et al. Infection with wild-type mumps virus in Army recruits temporally associated with MMR vaccine. Epidemiol Infect 1999;123:251-5.
29. Vyse A, Jin L. An RT-PCR assay using oral fluid samples to detect rubella virus genome for epidemiological surveillance. Mol Cell Probes 2002;16:93-7.
30. Jin L, Vyse A, Brown D. The role of RT-PCR assay of oral fluid for diagnosis and surveillance of measles, mumps and rubella. Bull World Health Organ 2002;80:76-7.
31. McDade J, Anderson B. Molecular epidemiology: applications of nucleic acid amplification and sequence analysis. Epidemiol Rev 1996;18:90-7.
32. Hanratty B, Holt T, Duffell E, et al. UK measles outbreak in non-immune anthroposophic communities: implications for the elimination of measles from Europe. Epidemiol Infect 2000;125:377-83.
33. McCann R, van den Bosch C, White J, et al. Outbreak of measles in an orthodox Jewish community. Eurosurveill Wkly 2000;4:000119.
34. Ramsay M, Jin L, White J, et al. The elimination of indigenous measles transmission in England and Wales. J Infect Dis (in press).
35. Morgan-Capner P, Wright J, Miller C, et al. Surveillance of antibody to measles, mumps, and rubella by age. BMJ 1988;297:770-2.
36. Osborne K, Gay N, Hesketh L, et al. Ten years of serological surveillance in England and Wales: methods, results, implications and action. Int J Epidemiol 2000;29:362-8.
37. Miller C, Miller E, Waight P. Rubella susceptibility and the continuing risk of infection in pregnancy. BMJ 1987;294:1277-8.
38. Miller E, Waight P, Vurdien J, et al. Rubella surveillance to December 1992: second joint report from the PHLS and National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev 1993;3:R35-40.
39. Miller E, Tookey P, Morgan-Capner P, et al. Rubella surveillance to June 1994: third joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev 1994;4:R146-52.
40. Miller E, Waight P, Gay N, et al. The epidemiology of rubella in England and Wales before and after the 1994 measles and rubella vaccination campaign: fourth joint report from the PHLS and the National Congenital Rubella Surveillance Programme. Commun Dis Rep Rev 1997;7:R26-32.
41. Tookey P, Peckham C. Surveillance of congenital rubella in Great Britain, 1971-96. BMJ 1999;318:769-70.
42. Calvert N, Cutts F, Irving R, et al. Measles immunity and response to revaccination among secondary school children in Cumbria. Epidemiol Infect 1996;116:65-70.
43. Miller C, Farrington C, Harbert K. The epidemiology of subacute sclerosing panencephalitis in England and Wales 1970-1989. Int J Epidemiol 1992;21:998-1006.
44. Research Unit of the Royal College of General Practitioners. A retrospective survey of the complications of mumps. J R Coll Gen Pract 1974;24:552-6.
45. White C, Koplan J, Orenstein W. Benefits, risks and costs of immunization for measles, mumps and rubella. Am J Public Health 1985;75:739-44.
46. Jones A, White J, Begg N. The impact of MMR vaccine on mumps infection in England and Wales. Commun Dis Rep 1991;9:R93-6.
47. Maguire H, Begg N, Handford S. Meningoencephalitis associated with MMR vaccine. Commun Dis Rep Rev 1991;6:R60-1.
48. Miller E, Goldacre M, Pugh S, et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993;341:979-82.
49. Ramsay M, Brown D, Eastcott H, et al. Salivary antibody testing and vaccination in a mumps outbreak. Commun Dis Rep Rev 1991;1:R96-8.
50. Cochi S, Preblud S, Orenstein W. Perspectives on the relative resurgence of mumps in the United States. Am J Dis Child 1988;142:499-507.
51. Dias J, Cordeiro M, Afzal M, et al. Mumps epidemic in Portugal despite high vaccine coverage - preliminary report. Eurosurveill Monthly 1996;1:25-8.
52. Anderson R, Grenfell B. Quantitative investigations of different vaccination policies for the control of congenital rubella syndrome (CRS) in the United Kingdom. J Hyg (Lond) 1986;96:305-33.
53. Knox E. Evolution of rubella vaccine policy for the UK. Int J Epidemiol 1987;16:569-78.
54. Sheridan E, Aitken C, Jeffries D, et al. Congenital rubella syndrome: a risk in immigrant populations. Lancet 2002;359:674-5.
55. Tookey P, Molyneaux P, Helms P. UK case of congenital rubella can be linked to Greek cases. BMJ 2000;321:766-7.
56. Rahi J, Adams G, Russel-Eggitt I, et al. Epidemiological surveillance of rubella must continue. (Letter). BMJ 2001;323:112.
57. Communicable Disease Surveillance Centre. Fall in MMR vaccine coverage reported as further evidence of vaccine safety is published. Commun Dis Rep CDR Wkly 1999;9:227,230.
58. Wakefield A, Murch S, Anthony A, et al. Ileal-lymphoidnodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 1998;351:637-41.
59. Communicable Disease Surveillance Centre. MMR vaccine coverage shows signs of recovery. Commun Dis Rep CDR Wkly 1999;9:345.
60. Uhlmann V, Martin CM, Sheils O, et al. Potential viral pathogenic mechanism for new variant inflammatory bowel disease. Mol Pathol 2002;55:84-90.
61. Miller E, Waight P, Farrington P. Safety assessment postlicensure. In: Plotkin S, Brown F, Horaud F, eds. Preclinical and clinical development of new vaccines. Basel, Switzerland: S. Karger AG, 1998:235-43.
62. McKie A, Vyse A, Maple C. Novel methods for the detection of microbial antibodies in oral fluid. Lancet Infect Dis 2002;2:18-24.